Clinical trial
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
NCT00234533 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00234533 |
|---|---|
| Title | Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq |
| Official title | Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method |
| Acronym | OPTIMA |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism |
| Intervention type | Drug |
| Interventions | Somatropin (rDNA origin) |
| Enrollment | 251 |
| Start date | Jun 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Oct 7, 2005 |
| Last update posted | Dec 9, 2019 |
| Countries | Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Romania, Russia, Slovakia, Spain and 2 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: